AIMS: To examine the effect of 24 weeks' rosuvastatin treatment on oxidative stress and changes in immune response to oxidized low-density lipoprotein (LDL). METHODS: This was an open-label study of patients in Austria receiving 10 or 40 mgrosuvastatin daily alternately during 12 and 24 weeks. Circulating concentrations of antibodies to malondialdehyde-oxidized LDL (MDA-LDL), both IgG and IgM type, to copper-oxidized LDL (Cu-OxLDL-IgG), concentrations of oxidized LDL complexed to IgG (OxLDL-IC) and markers of oxidative stress and systemic inflammation in subjects with plasma LDL cholesterol concentrations between 130 mg dl-1 and 250 mg dl-1 and triglycerides<or=400 mg dl-1 were determined. RESULTS: During statin therapy, plasma endogenous peroxides (POX-ACT) concentrations and peroxidase activity were significantly decreased, associated with a modest increase in total antioxidant capacity (TAC). Antibody titres to MDA-LDL-IgM, Cu-OxLDL-IgG and OxLDL-IC decreased, whereas MDA-LDL-IgG concentrations were increased after therapy. These changes were dose- and LDL-independent. POX-ACT concentrations were significantly positively correlated with inflammation markers before and after therapy and inversely with high-density lipoprotein-cholesterol concentrations after therapy. CONCLUSION: This study provides in vivo evidence that rosuvastatin significantly reduces oxidative stress and has immunomodulatory properties in a dose- and LDL-independent manner.
RCT Entities:
AIMS: To examine the effect of 24 weeks' rosuvastatin treatment on oxidative stress and changes in immune response to oxidized low-density lipoprotein (LDL). METHODS: This was an open-label study of patients in Austria receiving 10 or 40 mg rosuvastatin daily alternately during 12 and 24 weeks. Circulating concentrations of antibodies to malondialdehyde-oxidized LDL (MDA-LDL), both IgG and IgM type, to copper-oxidized LDL (Cu-OxLDL-IgG), concentrations of oxidized LDL complexed to IgG (OxLDL-IC) and markers of oxidative stress and systemic inflammation in subjects with plasma LDL cholesterol concentrations between 130 mg dl-1 and 250 mg dl-1 and triglycerides<or=400 mg dl-1 were determined. RESULTS: During statin therapy, plasma endogenous peroxides (POX-ACT) concentrations and peroxidase activity were significantly decreased, associated with a modest increase in total antioxidant capacity (TAC). Antibody titres to MDA-LDL-IgM, Cu-OxLDL-IgG and OxLDL-IC decreased, whereas MDA-LDL-IgG concentrations were increased after therapy. These changes were dose- and LDL-independent. POX-ACT concentrations were significantly positively correlated with inflammation markers before and after therapy and inversely with high-density lipoprotein-cholesterol concentrations after therapy. CONCLUSION: This study provides in vivo evidence that rosuvastatin significantly reduces oxidative stress and has immunomodulatory properties in a dose- and LDL-independent manner.
Authors: M K Chang; C Bergmark; A Laurila; S Hörkkö; K H Han; P Friedman; E A Dennis; J L Witztum Journal: Proc Natl Acad Sci U S A Date: 1999-05-25 Impact factor: 11.205
Authors: M Romano; A Mezzetti; C Marulli; G Ciabattoni; F Febo; S Di Ienno; S Roccaforte; S Vigneri; G Nubile; M Milani; G Davì Journal: J Investig Med Date: 2000-05 Impact factor: 2.895
Authors: S Hörkkö; D A Bird; E Miller; H Itabe; N Leitinger; G Subbanagounder; J A Berliner; P Friedman; E A Dennis; L K Curtiss; W Palinski; J L Witztum Journal: J Clin Invest Date: 1999-01 Impact factor: 14.808
Authors: M Aikawa; E Rabkin; Y Okada; S J Voglic; S K Clinton; C E Brinckerhoff; G K Sukhova; P Libby Journal: Circulation Date: 1998-06-23 Impact factor: 29.690
Authors: N Grosser; K Erdmann; A Hemmerle; G Berndt; U Hinkelmann; G Smith; H Schröder Journal: Biochem Biophys Res Commun Date: 2004-12-17 Impact factor: 3.575
Authors: Geannyne Villegas-Rivera; Luis Miguel Román-Pintos; Ernesto Germán Cardona-Muñoz; Oscar Arias-Carvajal; Adolfo Daniel Rodríguez-Carrizalez; Rogelio Troyo-Sanromán; Fermín Paul Pacheco-Moisés; Aldo Moreno-Ulloa; Alejandra Guillermina Miranda-Díaz Journal: Oxid Med Cell Longev Date: 2015-07-28 Impact factor: 6.543
Authors: Victor J van den Berg; Maxime M Vroegindewey; Isabella Kardys; Eric Boersma; Dorian Haskard; Adam Hartley; Ramzi Khamis Journal: Antioxidants (Basel) Date: 2019-10-15